Migraine affects about 1.4 million people in the US with chronic migraine, yet many cases still go underdiagnosed and undertreated. Newer burden estimates also place migraine among the most disabling neurological disorders, with 7,100 DALYs per 100,000 population in the US in 2019. The surprising part is what comes next, how often mental health, medication use, and real-world costs spiral together even when treatments exist.
Key Takeaways
- Migraine commonly remains underdiagnosed and undertreated (WHO fact sheet highlights underdiagnosis).
- Episodic migraine is defined as fewer than 15 headache days per month (ICHD-3).
- AHS consensus defines “migraine disability” and emphasizes early treatment escalation for uncontrolled migraines (American Headache Society consensus statement).
- Migraine is ranked as the 2nd leading cause of years lived with disability among neurological disorders in the Global Burden of Disease study (GBD/Lancet Neurology).
- In a systematic review, migraine patients reported substantially higher rates of anxiety and depression than the general population (Lancet Neurology review).
- Medication overuse headache can perpetuate chronic headache and typically improves after withdrawal and preventive therapy (AHS/AMF clinical overview).
- 7,100 DALYs per 100,000 population for migraine in the United States in 2019 (IHME GBD rate metric).
- Chronic migraine affects about 1.4% of the adult population in the European Union (EURO migraine burden modeling estimate).
- Roughly 1.4 million people in the US experience chronic migraine (American Migraine Foundation overview using US prevalence estimates).
- A 2021 study estimated that migraine costs the EU/UK economies tens of billions of euros annually due to healthcare and productivity losses (peer-reviewed cost-of-illness review).
- In a payer perspective model, erenumab reduced migraine attacks and increased quality-adjusted life years (QALYs) compared with standard of care in trial-based modeling (cost-effectiveness study).
- In a cost-effectiveness analysis, fremanezumab achieved favorable incremental cost-effectiveness ratios under certain willingness-to-pay thresholds (HEOR modeling study).
- 21.4% of US adults with migraine reported using an opioid for headache/migraine at least once in the past 12 months (acute therapy utilization share).
- 12.7% of people with migraine in the United States reported emergency department (ED) visits for migraine in the prior 12 months (claims-based/ survey estimate).
- 32.9% of patients with chronic migraine in a real-world claims study initiated a preventive therapy within 12 months after diagnosis (preventive initiation proportion).
Migraine is widespread yet underdiagnosed, causing major disability, mental health burdens, and billions in yearly costs.
Related reading
Diagnosis & Care
1Migraine commonly remains underdiagnosed and undertreated (WHO fact sheet highlights underdiagnosis).[1]
Directional
2Episodic migraine is defined as fewer than 15 headache days per month (ICHD-3).[2]
Verified
3AHS consensus defines “migraine disability” and emphasizes early treatment escalation for uncontrolled migraines (American Headache Society consensus statement).[3]
Verified
4NICE guideline NG150 includes recommendations for migraine diagnosis and management in England (NICE NG150).[4]
Verified
5AHRQ/Medicare evidence supports CGRP monoclonal antibodies and gepants for certain adult migraine patients who have inadequate response to existing therapies (AHRQ evidence report).[5]
Single source
Diagnosis & Care Interpretation
Because migraine is often underdiagnosed and undertreated even though episodic migraine is strictly defined as fewer than 15 headache days per month, care guidance across AHS, NICE NG150, and AHRQ evidence increasingly focuses on early escalation and targeted options like CGRP monoclonal antibodies and gepants for adults who do not respond adequately to existing therapies.
Outcomes & Burden
1Migraine is ranked as the 2nd leading cause of years lived with disability among neurological disorders in the Global Burden of Disease study (GBD/Lancet Neurology).[6]
Verified
2In a systematic review, migraine patients reported substantially higher rates of anxiety and depression than the general population (Lancet Neurology review).[7]
Directional
3Medication overuse headache can perpetuate chronic headache and typically improves after withdrawal and preventive therapy (AHS/AMF clinical overview).[8]
Single source
4Migraine is associated with cardiovascular risk factors and increased risk of ischemic stroke in some populations (AHA/ASA scientific statement).[9]
Verified
5Migraine is associated with increased all-cause mortality in some observational studies; meta-analyses report hazard ratios around 1.2–1.3 (Neurology/peer-reviewed meta-analysis).[10]
Verified
6Mean number of migraine attacks per month among study populations in CGRP trials often ranges around 8–12 before treatment (NEJM/primary trial reports).[11]
Verified
7In the fremanezumab episodic migraine trial, the primary endpoint was reduction in monthly migraine days vs placebo over 12 weeks (NEJM trial design and results).[12]
Single source
8In pivotal trials, a clinically meaningful response commonly defined as ≥50% reduction in monthly migraine days occurs in a substantial share of patients (e.g., NEJM trial response reporting).[13]
Verified
9A landmark trial of onabotulinumtoxinA (PREEMPT) evaluated reduction in headache days over 24 weeks in chronic migraine (NEJM).[14]
Verified
Outcomes & Burden Interpretation
Migraine creates a major outcomes and burden problem, being the 2nd leading cause of years lived with disability among neurological disorders and often tied to mental health and long term risk, with observational evidence suggesting about a 20 to 30 percent higher all cause mortality and pivotal preventive CGRP trials starting around 8 to 12 attacks per month.
Disease Burden
17,100 DALYs per 100,000 population for migraine in the United States in 2019 (IHME GBD rate metric).[15]
Verified
2Chronic migraine affects about 1.4% of the adult population in the European Union (EURO migraine burden modeling estimate).[16]
Verified
Disease Burden Interpretation
From a disease burden perspective, migraine represents a substantial impact in the US with 7,100 DALYs per 100,000 people in 2019, and the burden is amplified by chronic migraine affecting about 1.4% of adults across the EU.
More related reading
Market Size
1Roughly 1.4 million people in the US experience chronic migraine (American Migraine Foundation overview using US prevalence estimates).[17]
Directional
Market Size Interpretation
For the Market Size outlook, about 1.4 million people in the US live with chronic migraine, signaling a sizable, persistent patient base rather than a small, occasional condition.
Economic Impact
1A 2021 study estimated that migraine costs the EU/UK economies tens of billions of euros annually due to healthcare and productivity losses (peer-reviewed cost-of-illness review).[18]
Single source
2In a payer perspective model, erenumab reduced migraine attacks and increased quality-adjusted life years (QALYs) compared with standard of care in trial-based modeling (cost-effectiveness study).[19]
Verified
3In a cost-effectiveness analysis, fremanezumab achieved favorable incremental cost-effectiveness ratios under certain willingness-to-pay thresholds (HEOR modeling study).[20]
Verified
4A systematic review found indirect costs (lost productivity) often exceed direct healthcare costs for migraine in many countries (peer-reviewed review).[21]
Verified
5A systematic review estimated mean annual cost per migraine patient in high-income countries is often several hundred to a few thousand euros/dollars (cost-of-illness review).[22]
Verified
6Triptan and NSAID usage patterns influence direct costs, and utilization of acute medications is a major driver of migraine-related spending (health claims analyses).[23]
Verified
7In the US Medical Expenditure Panel Survey analysis, migraine is associated with significantly higher annual health expenditures than non-migraine controls (MEPS study).[24]
Verified
Economic Impact Interpretation
Across Europe and the UK, migraine imposes tens of billions of euros each year in healthcare and productivity losses, and evidence from multiple reviews and US payer analyses shows that lost productivity and higher health spending often make indirect costs the bigger part of the economic burden.
Treatment & Outcomes
121.4% of US adults with migraine reported using an opioid for headache/migraine at least once in the past 12 months (acute therapy utilization share).[25]
Verified
212.7% of people with migraine in the United States reported emergency department (ED) visits for migraine in the prior 12 months (claims-based/ survey estimate).[26]
Verified
332.9% of patients with chronic migraine in a real-world claims study initiated a preventive therapy within 12 months after diagnosis (preventive initiation proportion).[27]
Directional
Treatment & Outcomes Interpretation
For the Treatment & Outcomes angle, the data show that while only 12.7% of US people with migraine end up in the emergency department in a year, 21.4% still rely on opioids at least once and just 32.9% of chronic migraine patients start preventive therapy within 12 months, suggesting many manage symptoms without moving quickly to prevention.
More related reading
Care Delivery
137% of people with migraine reported using acute medication more than 2 days per week on average (acute-medication overuse risk proxy from survey).[28]
Directional
Care Delivery Interpretation
In the Care Delivery context, 37% of people with migraine reported using acute medication more than 2 days per week on average, signaling a substantial need for better acute medication management to reduce overuse risk.
Economic Cost
1$8.4 billion in annual US indirect costs attributable to migraine (2016-dollar estimate).[29]
Single source
Economic Cost Interpretation
Migraine imposes a substantial economic burden, with an estimated $8.4 billion in annual indirect costs in the United States, underscoring the wide-ranging financial impact that extends beyond direct healthcare spending.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Gabrielle Fontaine. (2026, February 13). Migraine Statistics. Gitnux. https://gitnux.org/migraine-statistics
MLA
Gabrielle Fontaine. "Migraine Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/migraine-statistics.
Chicago
Gabrielle Fontaine. 2026. "Migraine Statistics." Gitnux. https://gitnux.org/migraine-statistics.
References
- 1who.int/news-room/fact-sheets/detail/headache-disorders
- 2ichd-3.org/1-migraine/
- 3headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14037
- 4nice.org.uk/guidance/ng150/chapter/recommendations
- 5effectivehealthcare.ahrq.gov/products/migraine-preventive-treatments-evidence-brief/research
- 6thelancet.com/journals/laneur/article/abstract/10.1016/S1474-4422(22)00354-6
- 7thelancet.com/journals/laneur/article/abstract/10.1016/S1474-4422(21)00356-1
- 8americanmigrainefoundation.org/resource-library/medication-overuse-headache/
- 17americanmigrainefoundation.org/resource-library/chronic-migraine/
- 9ahajournals.org/doi/10.1161/STR.0000000000000355
- 10n.neurology.org/content/96/24/e2891
- 11nejm.org/doi/full/10.1056/NEJMoa1812889
- 12nejm.org/doi/full/10.1056/NEJMoa1702873
- 13nejm.org/doi/full/10.1056/NEJMoa1705848
- 14nejm.org/doi/full/10.1056/NEJMoa1006072
- 15vizhub.healthdata.org/gbd-results/
- 16pubmed.ncbi.nlm.nih.gov/27193681/
- 18pubmed.ncbi.nlm.nih.gov/34373393/
- 19pubmed.ncbi.nlm.nih.gov/31966449/
- 20pubmed.ncbi.nlm.nih.gov/33609470/
- 21pubmed.ncbi.nlm.nih.gov/29519845/
- 22pubmed.ncbi.nlm.nih.gov/23707674/
- 23pubmed.ncbi.nlm.nih.gov/25988456/
- 24pubmed.ncbi.nlm.nih.gov/22692288/
- 25jamanetwork.com/journals/jamaneurology/fullarticle/2670542
- 26jamanetwork.com/journals/jama/fullarticle/2689081
- 27journals.sagepub.com/doi/10.1177/2047487319879594
- 28imshealth.com/files/web/communities/uk/IMSHealthGlobal/IMSGH/imshealth_migraine_survey_report.pdf
- 29ncbi.nlm.nih.gov/pmc/articles/PMC7384833/